

1 Small apolipoprotein(a) isoforms may predict primary patency following peripheral arterial
2 revascularization.

3

4 Short Title: Apo(a) size and peripheral revascularization

5

6 Marianna Pavlyha¹, Madeleine Hunter², Roman Nowygrod², Virenda Patel², Nicholas

7 Morrissey², Danielle Bajakian², Yihao Li¹, Gisette Reyes-Soffer¹

8

9 ¹Department of Medicine, Division of Preventive Medicine and Nutrition, Columbia University

10 Vagelos College of Physicians and Surgeons, New York, NY

11 ²Department of Surgery, Division of Vascular Surgery, Columbia University Vagelos College of

12 Physicians and Surgeons, New York, NY

13

14 Corresponding Author:

15

16 Gisette Reyes-Soffer

17 630 West 168th street

18 P&S 10th floor, room 501

19 New York, NY 10032

20 Office: (212) 305-9298

21 gr2104@cumc.columbia.edu

22

23 **The authors have no competing interest**

1 **ARTICLE HIGHLIGHTS**

2 **Type of Research:**

3 Single-center prospective cohort study

4

5 **Key Findings:**

6 25 subjects with symptomatic PAD underwent open or
7 endovascular lower extremity revascularization in a small
8 cohort. Smaller apo(a) isoforms were associated with
9 occlusion of the treated lesion(s) within 2-4 weeks
10 [OR=1.97 (95% CI 1.01 - 3.86, p<0.05)], suggesting
11 apo(a) isoform size as a predictor of primary patency in
12 the early period after lower extremity intervention.

13

14 **Take Home Message:**

15 Subjects with high Lp(a) levels, generally have smaller
16 apo(a) isoform sizes. We find that, in this small cohort,
17 patients undergoing peripheral arterial revascularization
18 subjects with small isoforms are at an increased risk of
19 treated vessel occlusion in the perioperative period.

20

21 **Table of Contents Summary**

22 Subjects with symptomatic PAD requiring lower
23 extremity revascularization have high median Lp(a)

1 levels. Individuals with smaller apo(a) weighted isoform
2 size (*wIS*) have lower primary patency rates and/or
3 require re-intervention.

4

5 **Key Words:** peripheral arterial disease, lipids, Lipoprotein(a), apo(a), isoforms

6

7 **Abstract**

8 Background: High lipoprotein (a) [Lp(a)] is associated with adverse limb events in patients
9 undergoing lower extremity revascularization. Lp(a) levels are genetically pre-determined, with
10 *LPA* gene encoding for two apolipoprotein (a) [apo(a)] isoforms. Isoform size variations are
11 driven by the number of kringle IV type 2 (KIV-2) repeats. Lp(a) levels are inversely correlated
12 with isoform size. In this study, we examined the role of Lp(a) levels, apo(a) size and
13 inflammatory markers with lower extremity revascularization outcomes.

14

15 Methods: 25 subjects with chronic peripheral arterial disease (PAD), underwent open or
16 endovascular lower extremity revascularization (mean age of 66.7±9.7 years; F=12, M=13;
17 Black=8, Hispanic=5, and White=12). Pre- and post-operative medical history, self-reported
18 symptoms, ankle brachial indices (ABIs), and lower extremity duplex ultrasounds were obtained.
19 Plasma Lp(a), apoB100, lipid panel, and pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNF α)
20 were assayed preoperatively. Isoform size was estimated using gel electrophoresis and weighted
21 isoform size (*wIS*) calculated based on % isoform expression. Firth logistic regression was used
22 to examine the relationship between Lp(a) levels, and *wIS* with procedural outcomes: symptoms

1 (better/worse), primary patency at 2-4 weeks, ABIs, and re-intervention within 3-6 months. We
2 controlled for age, sex, history of diabetes, smoking, statin, antiplatelet and anticoagulation use.
3
4 Results: Median plasma Lp(a) level was 108 (44, 301) nmol/L. The mean apoB100 level was
5 168.0 ± 65.8 mg/dL. These values were not statistically different among races. We found no
6 association between Lp(a) levels and *wIS* with measured plasma pro-inflammatory markers.
7 However, smaller apo(a) *wIS* was associated with occlusion of the treated lesion(s) in the
8 postoperative period [OR=1.97 (95% CI 1.01 - 3.86, $p < 0.05$)]. The relationship of smaller apo(a)
9 *wIS* with re-intervention was not as strong [OR=1.57 (95% CI 0.96 - 2.56), $p = 0.07$]. We
10 observed no association between *wIS* with patient reported symptoms or change in ABIs.
11
12 Conclusions: In this small study, subjects with smaller apo(a) isoform size undergoing peripheral
13 arterial revascularization were more likely to experience occlusion in the perioperative period
14 and/or require re-intervention. Larger cohort studies identifying the mechanism and validating
15 these preliminary data are needed to improve understanding of long-term peripheral vascular
16 outcomes.

17

18 **Introduction**

19 Lipoprotein (a) [Lp(a)] is causal for the development of atherosclerotic cardiovascular disease
20 (ASCVD) and atherothrombosis as shown in epidemiological, Mendelian Randomization, and
21 genome wide association studies (GWAS) ¹. Elevated Lp(a) levels are independently associated
22 with incidence of major adverse cardiovascular events (MACE) and major adverse limb events
23 (MALE) after lower extremity endovascular ² or open surgery ³ while controlling for other risk

1 factors. Despite this, measurement of Lp(a) levels is not standard of care in those undergoing
2 vascular intervention. Lp(a) particles contain two main apolipoproteins: B100 [apoB100] and
3 apolipoprotein(a) [apo(a)]. Individuals can express one or two apo(a) isoforms and these vary in
4 size depending on the number of Kringle-IV type 2 (KIV-2) repeats that are encoded by the *LPA*
5 gene. Plasma Lp(a) levels and apo(a) isoform size are inversely correlated, with smaller
6 isoforms generally dominating¹. There are well described mechanisms linking high levels of
7 Lp(a) and atherosclerosis, including complement activation, inflammatory, and coagulation
8 pathways¹. Apo(a) can potentiate atherothrombosis through presence of lysine binding sites that
9 allow accumulation of lipid in the arterial wall and activation of inflammatory pathways,
10 owing to its binding of oxidized phospholipids (OxPL)^{4 5}. High Lp(a) levels have also been
11 association with enhanced expression of adhesion molecules in endothelial cells and pro-
12 inflammatory interleukins in monocytes and macrophages⁶. Finally, apo(a) has evolved from
13 the plasminogen gene through duplication and remodeling⁷ and its homology with plasminogen
14 allows it to compete for its binding site, inhibiting thrombolysis and indirectly promoting a
15 prothrombotic state. These mechanisms are of interest in vascular patency.

16
17 Numerous studies show that high Lp(a) levels are associated with increased incidence of
18 claudication, symptoms progression, re-stenosis after intervention, hospitalization, and limb
19 amputation⁸, and those with high Lp(a) have a higher risk of combined PAD outcomes after
20 adjusting for other traditional risk-factors. Few studies, however, have looked at the association
21 between apo(a) isoform size and peripheral arterial surgical outcomes. Available data suggests
22 that both increased Lp(a) levels and the presence of small apo(a) isoforms are associated with the
23 increased incidence of symptomatic PAD^{9 10}. Whereas small apo(a) isoforms were shown to be

1 independently associated with three-fold increase in risk of major adverse cardiovascular events
2 after coronary artery bypass grafting (CABG) at long term follow up ¹¹, the role of this Lp(a)
3 component on lower limb outcomes have not been explored. In view of previous findings and
4 needs in the field, we developed a study using available stored plasma samples and outcomes
5 data on subjects with PAD who underwent lower extremity revascularization, yet they had no
6 history of Lp(a) measurement. We examined the relationships between apo(a) isoform size,
7 primary patency, and rate of re-intervention. In addition, given apo(a)'s role in propagating the
8 inflammatory cascade implicated in atherosclerotic plaque formation ^{12 13 14}, the relationship of
9 pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNF α) with apo(a) size and surgical outcomes
10 were investigated.

11
12 There are current studies focused on lowering Lp(a) by targeting the apo(a) component in phase
13 3 of development ¹⁵, highlighting the need to understand which populations are at increased
14 disease risk and would benefit from treatment. Our small study provides preliminary insights that
15 can be used to design larger studies in patients with advanced PAD. These studies may assist
16 with improving risk prediction, stratification, and medical optimization of surgical patients with
17 high Lp(a).

18

19 **Methods**

20 We analyzed data from all 27 participants recruited from the Columbia University Irving
21 Medical Center (CUIMC) Vascular Surgery Clinic into a prospective cohort study
22 [Anthropometric and Biomarker Assay, and Lower Extremity Arterial Revascularization
23 (ABALEAR)] between June 2018 and March 2021, **Supplemental Figure 2**. The study protocol

1 was approved by the CUIMC Institutional Review Board (AAAL7756). Inclusion criteria
2 encompassed adult subjects with a clinical diagnosis of PAD, who were planned to undergo non-
3 emergent revascularization (open or endovascular) of the affected lower extremity. Those with
4 ischemic wounds, active infectious process, or cardiovascular intervention within 12 months of
5 enrollment were excluded. Two of the participants who underwent only diagnostic angiogram
6 were also excluded from final analysis. The type of intervention was at the discretion of the
7 treating provider.

8
9 *Recruitment/Enrollment:* Subjects that met inclusion and exclusion criteria were contacted prior
10 to their scheduled operation and informed consent was obtained. Medical and social history were
11 collected by a licensed health professional, including demographic information (age, sex, self-
12 reported race-ethnicity (SRRE)), history of smoking, hypertension (HTN), diabetes, carotid
13 artery disease (CAD) or dyslipidemia. Medication use [antihypertensives, statins, antiplatelet
14 (AP), direct oral anticoagulant (DOAC)] and symptoms of rest pain or claudication (ambulatory
15 distance in city blocks) were recorded. A pre-operative physical exam was performed, which
16 included distal pulses, a lower extremity arterial duplex ultrasound (US), ankle brachial index
17 (ABI), and body mass index (BMI). On the day of the surgical procedure, arterial blood samples
18 were collected using EDTA tubes; plasma was separated and stored at -80°C .

19
20 *Study Follow-up (2-4 weeks and 3-6 months):* Participants were seen in the office for their post-
21 operative visits by their respective providers. During these visits, physical exam (pulses, US,
22 ABIs) to assess for primary patency and the trajectory of self-reported subjective symptoms were
23 determined based on presence or resolution of rest pain and changes in walking distance. These

1 were then categorized as ‘improved,’ ‘worsened’ or ‘stayed the same.’ In cases of multiple
2 vessels intervention, absent blood flow in the most proximal intervened vessel constituted
3 occlusion. If multiple vessels below the popliteal artery trifurcation were intervened on,
4 multiphasic in-line flow preserved in at least one of the vessels constituted patency. Palpable
5 pulses over the graft and distally constituted patency. Two subjects did not have a complete US
6 assessment at first follow-up and were excluded from sub-analysis. Change in ABI¹⁶
7 measurements were categorized as improved from pre-operative measurement vs not improved
8 (worsened or the same). Of note, ABI measurements falsely elevated due to calcified non-
9 compressible vessels, incomplete, or missing for at least one of the visits were excluded from the
10 sub-analysis. Hence, the available ABI data is limited. Toe pressures were not available on this
11 cohort. In addition to the above, the 3-6 months visit included records of any interval
12 interventions on the ipsilateral extremity.

13
14 Plasma Lp(a), apoB100, lipids [triglycerides (TG), total cholesterol(C), high density lipoprotein
15 (HDL)] were automatically measured on Integra 400 plus (Roche). Plasma LDL-C levels were
16 calculated using the Friedewald formula (one subject had a TG level >400mg/dL and was not
17 reported). Plasma apoB100 levels were measured by a human enzyme-linked immunosorbent
18 assay (ELISA) from Mabtech, Inc, Cincinnati, OH. Lp(a) plasma concentration were measured
19 using the isoform-independent sandwich ELISA developed by the Northwest Lipid Metabolism
20 and Diabetes Research Laboratory at Medpace, Inc. Apo(a) isoform size measurements were
21 performed by the same laboratory using agarose gel electrophoresis. ChemiDoc MP Imaging
22 System was used to determine the isoforms using in-house standards and relative expression of
23 each isoform was reported. Weighted isoform size (*wIS*) was calculated using the % isoform

1 expression (two isoform masses were multiplied by their relative expression). Pro-inflammatory
2 markers Interleukin-6 (IL6), Interleukin-18 (IL-18) were measured using ELISA kits (D6050,
3 R&D Systems, Minneapolis, MN) and (DY318-05, R&D Systems, Minneapolis, MN),
4 respectively. High sensitivity C-reactive protein (hs-CRP) and Tumor Necrosis Factor alpha
5 (TNF α) were measured on an Integra400plus (Roche) using standardized methods at the Irving
6 Institute for Clinical and Translational Research Biomarkers laboratory at CUIMC.

7

8 **Statistical Analysis**

9 All data were analyzed using standard R software (Version 4.2.2). Normally distributed variables
10 were summarized by means and standard deviations (SD). Lp(a) levels and TGs were
11 summarized by median and interquartile range. The relationship of Lp(a) levels with *wIS* in the
12 three SRRE groups was studied by Analysis of Variance (ANOVA). Racial differences in Lp(a)
13 levels and *wIS* were assessed using the median test. Due to small samples size, an
14 implementation based on the Firth logistic regression¹⁷ was chosen to examine the relationship
15 between *wIS* with procedural outcomes: change in symptoms, primary patency of treated
16 lesion(s), change in ABIs, and re-intervention within 3-6 months. Results were reported as odds
17 ratios (OR). Sex, age, smoking status, history of diabetes, statin, antiplatelet and DOAC use were
18 considered as potential confounders, according to the literature, and were included in the
19 regression^{18 19 20 21}. HTN and BMI were not integrated into the model based on their role in
20 published studies of surgical outcomes^{22 23}. We did not control for history of CAD, as literature
21 shows that most individuals with diagnosis of PAD have some degree of CAD and at least 60%
22 have significant CAD²⁴.

23

1 **Results**

2 *Baseline Characteristics:* Subject demographics, lipid and lipoprotein levels are shown in **Table**

3 **I.** The study population included 12 females and 13 males with a mean age of 66.7 ± 9.7 years.

4 Our cohort was multiethnic with 8 Blacks, 5 Hispanics, and 12 Whites, representative of the

5 available population at our institution. All subjects were Rutherford stage 3 and 4. 5 subjects

6 underwent open revascularization and 20, endovascular. Majority of the subjects underwent

7 infra-inguinal intervention (N=23) and 6 required re-intervention within 3-6 months. Individuals

8 were mildly overweight and lipid levels consistent with a population being treated for

9 dyslipidemia. Despite use of lipid lowering therapies, the mean apoB100 levels were $168.0 \pm$

10 65.8 mg/dL. Median plasma Lp(a) level was 108 (44, 301) nmol/L. Primary patency rates at 2-4

11 weeks and 3-6 months were 76% and 68%. Rate of re-intervention measured at 3-6-months visit

12 was 24%.

13

14 *Lp(a) levels and Isoform Size:* Previous reports show that high Lp(a) levels are associated with

15 worse outcomes after surgical intervention. We found that most of the individuals in our cohort

16 had high Lp(a) levels. The mean *wIS* was 18.4 ± 4.1 and as expected, there was an inverse

17 relationship between Lp(a) levels and *wIS* ($R^2 = 0.20$; $p=0.02$), **Figure 1**. Most individuals

18 express two apo(a) isoforms, however in our small diverse cohort, we found that half (N=12)

19 individuals expressed only a single isoform, **Supplemental Table I**, with predominance of the

20 small isoform, **Figure 2**.

21

22 *Relationship of Lp(a) levels and Isoforms with surgical outcomes:* We did not find significant

23 associations between Lp(a) levels and post-surgical symptoms, ABI, primary patency, or re-

1 intervention, **Table IIb**. Surgery type did not affect this result. However, *wIS* was significantly
2 correlated with primary patency at 2-4 weeks [OR=1.97 (95% CI 1.01 - 3.86, $p<0.05$)], **Table**
3 **IIa**. Controlling for SRRE did not change these study outcomes. We observed a trend between
4 *wIS* and re-intervention in the 3-6 months period [OR=1.57 (95% CI 0.96 - 2.56), $p=0.07$].
5 When we used predominant apo(a) isoform size as the primary variable in our model, and
6 adjusted for plasma Lp(a) levels, our observed effect of apo(a) size on primary patency remained
7 statistically significant [OR=2.01, (CI 1.03 - 3.93) $p<0.05$], suggesting that apo(a) was a stronger
8 a predictor of outcomes compared to Lp(a) levels in this cohort.

9
10 The type of surgical procedure could have affected our study outcomes, however when we
11 assessed the relationship between *wIS* isoform size and primary patency for subjects that only
12 underwent endovascular intervention, we noted a similar trend [OR=1.67 (95% CI 0.95 - 2.94),
13 $p=0.08$]. We did not see an association between *wIS* and patient reported symptoms or change in
14 ABIs at 3-6 months. It is notable, however, that our sample size for analysis of ABIs was much
15 smaller (N=14) due to inability of all subjects to undergo the test reliably (ex. pain, non-
16 compliant calcified vessels resulting in falsely elevated results) or missing measurement from
17 some visits.

18
19 As expected, inflammatory markers IL-18 and hs-CRP were higher in this cohort when
20 compared to published levels in healthy cohorts, **Table III**. However, we found no significant
21 relationship between plasma Lp(a) levels or *wIS* with IL-6, IL-18, hs-CRP, or TNF α .
22 Additionally, inflammatory markers were not associated with our surgical outcomes.

23

24

1 **Discussion**

2 High Lp(a) levels are associated with adverse limb events in patients with symptomatic PAD
3 undergoing lower extremity revascularization^{25 26 2}. International guidelines (Canadian²⁷ and
4 ECC²⁸) advocate for all individuals to have Lp(a) measured once in a lifetime. In the United
5 States, the American Heart Association (AHA) suggest using Lp(a) levels as a ‘risk enhancer’²⁹.
6 However, there are no specific guidelines for Lp(a) measurements in patients with advanced
7 PAD that are referred for surgical intervention. All subjects in our study have been diagnosed
8 with at least one metabolic disease, however, they were not screened for Lp(a) by their primary
9 providers; and the majority were found to have elevated levels.

10

11 Although our study sample is small, which limits the generalizability of the results, it features a
12 good representation based on gender and race. These data can be used to develop well controlled
13 cross-sectional studies that can examine the role of apo(a) in larger populations with PAD. Most
14 individuals at risk or that have ASCVD, obtain laboratory measurement of low-density
15 lipoprotein cholesterol (LDL-C), an apoB100 containing particle. Physicians rely on these
16 measurements for prescribing lipid therapies, such as statins, in clinical practice. We observed
17 that in our cohort, 76% of individuals were prescribed statins. While statins significantly lower
18 LDL-C, they tend to increase Lp(a) by about 11%¹. It is important to note, however, that the
19 laboratory levels of LDL-C in plasma are known to be confounded by the presence of Lp(a)-C³⁰,
20 which contains both apoB100 and apo(a). The reason for this overlap lies in similar plasma
21 densities between Lp(a) and LDL particles. Thus, in patients with high levels of Lp(a) the actual
22 LDL-C is lower from the reported value and some investigators believe apoB100 to be a more
23 accurate measure of cardiovascular risk compared to LDL-C³¹. This is important, because most

1 vascular patients are prescribed statins, which works via increased LDL receptor expression,
2 facilitating clearance of LDL-C, but not Lp(a). Patients that have elevated LDL-C while on
3 optimal LDL lowering therapy would benefit from having their Lp(a) measured and treated, as
4 there is a high probability that the increased cholesterol is carried by Lp(a) particles. We observe
5 this in some patients in our population as well and this may explain why some patients, despite
6 LDL-C lowering by statins, remain at risk³². Two out of 19 subjects in the study who were taking
7 statins had above normal LDL-C levels; both had Lp(a) measurements > 200 nmol/L. In this
8 population where Lp(a) is high, this particle may carry most of the cholesterol.
9
10 Whereas there has been great interest in Lp(a) levels and surgical outcomes, few studies have
11 looked at the role of apo(a) size in vascular surgery, and specifically, there are no existing reports
12 on patency after lower extremity revascularization. The *LPA* gene encodes for two apo(a)
13 isoforms that comprise the Lp(a) particle. Variations in size of the apo(a) isoforms are driven by
14 the number of KIV-2 repeats. Small number of KIV-2 repeats lead to small apo(a) size and are
15 associated with higher Lp(a) levels, posing an increased risk for cardiovascular disease,
16 including PAD⁹. Similar to other cohorts¹, the current study finds an inverse association
17 between plasma Lp(a) levels and apo(a) allele size, with smaller isoforms associated with higher
18 Lp(a) levels³³. Whereas ~20% of the general population is expected to have high Lp(a) and
19 express two apo(a) isoforms¹, close to half of our subjects with high median Lp(a) expressed
20 only one isoform size, **Supplemental Table I**. Previous studies in individuals with PAD showed
21 that both increased Lp(a) serum concentrations (75th percentile) and the small apo(a) phenotype
22 are strongly associated with symptomatic PAD, independent of other confounders⁹. We did not
23 see any significant correlation between Lp(a) levels and outcomes, but when controlled for Lp(a)

1 levels, the predictive association of *wIS* with primary patency was still statistically significant.
2 Although data in the literature regarding disease predictability of Lp(a) vs apo(a) is conflicting,
3 there is evidence that the strength of the association is higher for apo(a) isoform size in certain
4 diseases³⁴. To our knowledge, there are no reports assessing the correlation between apo(a) size
5 and primary patency. Our preliminary study finds that small apo(a) size strongly correlates with
6 primary patency within 2-4 weeks with a trend towards a higher rate or re-intervention at 3-6
7 months. Although more comprehensive evaluation of the prognostic relationship between apo(a)
8 size and these outcomes of peripheral arterial interventions would be served in a randomized or
9 cross-sectional study, these results support what is already known about apo(a)'s mode of action.
10 We postulate that the probable mechanisms lie in the apo(a)'s kringle structure having homology
11 with fibrinolytic proenzyme plasminogen, but inactive in fibrinolysis. Small apo(a) isoform size
12 resulting from low *LPA* KIV-2 number of repeats can slow fibrinolysis and thus indirectly
13 promote thrombosis, leading to increased risk of perioperative complications such as graft
14 occlusion or thromboembolic events³⁵. Additionally, apo(a) potentiates thrombosis by binding
15 and inactivating tissue factor pathway inhibitor (TFPI)³⁶. This is especially important, as many
16 of peripheral arterial intervention are performed to aid in wound healing and this period may be
17 imperative for patients with tissue loss. These pro-thrombotic action of the apo(a) could also
18 explain the high rate of early re-intervention in this cohort of patients with high Lp(a),
19 particularly as 5 our 6 subjects in the group requiring re-intervention had small apo(a),

20 **Supplemental Figure 1.**

21

22 A study from a UK biobank studied approximately 460 thousand participants and showed
23 significant differences in Lp(a) concentrations across racial subgroups, specifically with higher

1 Lp(a) levels seen within South Asian and Black population compared to Whites³⁷. Although on
2 average Hispanics had higher values than Whites in our cohort, there were no statistically
3 significant differences in Lp(a) values and apo(a) size among different races and race had no
4 impact on most surgical outcomes. This could be due to our limited sample size.

5
6 Some of Lp(a)'s role in disease risk has been linked to inflammatory profiles. Specifically,
7 elevated TNF- α , IL-6, and CRP levels^{12,38} at baseline correlate with worse vascular outcomes in
8 patients with diabetes, PAD, and chronic limb-threatening ischemia undergoing endovascular
9 procedures¹⁴. We did not find any significant correlations with circulating inflammatory markers
10 and Lp(a), *w/IS* or surgical outcomes, however, we did not measure OxPLs which may add new
11 information in PAD patients as it has in other described populations³⁹. Of note, it has also been
12 reported that statins decreased the serum levels of hs-CRP¹² and downregulate IL-6¹³. Majority
13 of our subjects were taking high-dose statins (which also tend to increase Lp(a)) and may be
14 contributing to our observations.

15
16 Although there are no currently available targeted therapies to treat high Lp(a), some agents
17 available in the United States that lower apoB100 and LDL-C also decrease Lp(a) modestly,
18 such as niacin, Ezetimibe, and PCSK9 inhibitors. The FDA has also recently approved
19 lipoprotein apheresis for high-risk cases with Lp(a) >60mg/dL and LDL-C >100 mg/dL and with
20 either documented CAD or PAD¹. The two apo(a) targeted therapies, antisense oligonucleotides
21 and siRNA and are also in phase 3 studies and are expected to report their initial results in 2024.
22 While we wait for this data, new studies now suggest the benefit of DAPT in patients with high
23 Lp(a)⁴⁰. Particularly, recent outcomes in these patients undergoing percutaneous coronary

1 intervention (PCI), showed that prolonged DAPT (>1 year) reduced ischemic cardiovascular
2 events, all-cause mortality, cardiac mortality, and definite/probable stent thrombosis, without
3 increase in clinically relevant bleeding risk compared with \leq 1-year DAPT⁴¹. Data from this
4 small study cohort raise the question whether we need to rethink risk assessment and post-
5 operative management in patients high Lp(a) and small apo(a) size undergoing lower extremity
6 interventions. As the importance of Lp(a) becomes more recognized in clinical practice^{37,42}, and
7 we review cardiovascular outcome data from phase 3 apo(a) targeted treatments, developing
8 larger studies that have more stringent control of patient selection and type of intervention would
9 serve as the next step in validating the generalizability of the current findings.

10

11 Understanding the impact of apo(a) isoform size on Lp(a) levels and surgical outcomes may
12 guide risk stratification and therapeutic decision-making when it comes to pre-operative
13 optimization and medical management post-operatively. Lp(a) levels are stable throughout
14 lifetime. Although measuring apo(a) size may not be feasible in all patients and it currently not
15 used in clinical practice, as genetic testing becomes more widely available, assessing KIV-2 size
16 associated with the *LPA* gene may help identify individuals at higher risk of developing PAD
17 and worse outcomes. Given Lp(a) genetic predisposition and low variability of levels throughout
18 lifetime, one measurement may be sufficient and is the standard of care in many European
19 countries²⁸.

20

21 Further research in larger cohorts is needed to establish a more robust understanding of the
22 mechanisms and impact of apo(a) isoform size on surgical outcomes in patients PAD.

1 Randomized clinical trials to explore potential medical therapy strategies to mitigate associated
2 risks would aid in providing guidelines for perioperative management of these individuals.

3

4 **Study Limitations**

5 Overall, this was a sample of convenience. Subject samples and prospectively collected data
6 from ongoing biomarker study (ABALEAR) were available to our lipid team to examine
7 additional affecters on surgical outcomes. Although subject baseline characteristics are
8 comparable to larger cohorts, we acknowledge that sample size is small and significantly limit
9 the generalizability of the results. We used firth logistics regression to account for small sample
10 size. Additionally, the cohort is heterogenous in terms of presenting symptoms with surgical
11 interventions geared towards each patient's needs, but ultimately 'no leg is alike,' and the cohort
12 represents a diverse spectrum of lower extremity disease and intervention seen in vascular
13 surgery clinics. Additionally, due to limited size, associations between peripheral interventions
14 and Lp(a) levels/apo(a) size was done without correction for multiple testing.

15

16 **Conclusion**

17 In this limited cohort, most subjects with chronic symptomatic PAD had elevated Lp(a) levels
18 without being screened by their medical providers outside of the study, pointing to the need to
19 increase awareness for Lp(a) screening in vascular patients. Small apo(a) isoform expression
20 could be an important risk predictor not only for the development of PAD, which has already
21 been established in literature, but also as a driver of worse short term surgical outcomes. Further
22 studies identifying the mechanism and relationship of these findings to long-term peripheral

1 vascular outcomes are warranted, specifically identifying the role of apo(a) size among different
2 sexes and races in larger well controlled cohorts.

3

4 **Acknowledgements**

5 We would like to acknowledge Anastasiya Matveyenko¹ and Srinivas Cherukuri¹ for their
6 assistance with study conduction and laboratory measurements. **Funding** for this study was
7 provided by T32HL007343 (M.P.), UL1TR001873 (G.R.S), partial funding for MP stipend and
8 manuscript processing funds were supported by a donation from Robin Chemers Neustein to the
9 Reyes-Soffer Laboratory.

10

1 **References**

- 2
- 3 1. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones
4 DM, Marcovina SM, Yeang C, Koschinsky ML, et al. Lipoprotein(a): A Genetically
5 Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular
6 Disease: A Scientific Statement From the American Heart Association. *Arterioscler*
7 *Thromb Vasc Biol.* 2022;42:e48-e60.
- 8 2. Tomoi Y, Takahara M, Soga Y, Kodama K, Imada K, Hiramori S, Ando K. Impact of High
9 Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy.
10 *JACC Cardiovasc Interv.* 2022;15:1466-1476. doi: 10.1016/j.jcin.2022.05.050
- 11 3. Verwer MC, Waissi F, Mekke JM, Dekker M, Stroes ESG, de Borst GJ, Kroon J, Hazenberg
12 C, de Kleijn DPV. High lipoprotein(a) is associated with major adverse limb events after
13 femoral artery endarterectomy. *Atherosclerosis.* 2022;349:196-203. doi:
14 10.1016/j.atherosclerosis.2021.11.019
- 15 4. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and
16 Emerging Therapies. *J Am Coll Cardiol.* 2017;69:692-711. doi: 10.1016/j.jacc.2016.11.042
- 17 5. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger
18 S, Oberhollenzer F, et al. Oxidized phospholipids predict the presence and progression
19 of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-
20 year prospective results from the Bruneck study. *J Am Coll Cardiol.* 2006;47:2219-2228.
21 doi: 10.1016/j.jacc.2006.03.001
- 22 6. Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements:
23 Lipoprotein(a) and inflammation. *Pharmacol Res.* 2021;169:105689. doi:
24 10.1016/j.phrs.2021.105689
- 25 7. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of
26 lipoprotein (a). *J Lipid Res.* 2016;57:1339-1359. doi: 10.1194/jlr.R067314
- 27 8. Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated
28 lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic
29 review. *Vasc Med.* 2022;27:385-391. doi: 10.1177/1358863X221091320
- 30 9. Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M,
31 Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low
32 molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic
33 peripheral arterial disease. *Clin Chem.* 2007;53:1298-1305. doi:
34 10.1373/clinchem.2007.088013
- 35 10. Molgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant
36 association between low-molecular-weight apolipoprotein(a) isoforms and intermittent
37 claudication. *Arterioscler Thromb.* 1992;12:895-901. doi: 10.1161/01.atv.12.8.895
- 38 11. Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a)
39 level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular
40 outcomes after coronary artery bypass grafting. *Atherosclerosis.* 2014;235:477-482. doi:
41 10.1016/j.atherosclerosis.2014.05.944
- 42 12. Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, Shafiekhani S,
43 Mohammadi K, Jamialahmadi T, Reiner Z, et al. Effect of Statins on Serum level of hs-
44 CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-

- 1 Analysis of Randomized Controlled Trials. *Mediators Inflamm.* 2022;2022:8732360. doi:
2 10.1155/2022/8732360
- 3 13. Sepehri Z, Masoumi M, Ebrahimi N, Kiani Z, Nasiri AA, Kohan F, Sheikh Fathollahi M,
4 Kazemi Arababadi M, Asadikaram G. Atorvastatin, Losartan and Captopril Lead to
5 Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and
6 Hypertension. *PLoS One.* 2016;11:e0168312. doi: 10.1371/journal.pone.0168312
- 7 14. Biscetti F, Ferraro PM, Hiatt WR, Angelini F, Nardella E, Cecchini AL, Santoliquido A,
8 Pitocco D, Landolfi R, Flex A. Inflammatory Cytokines Associated With Failure of Lower-
9 Extremity Endovascular Revascularization (LER): A Prospective Study of a Population
10 With Diabetes. *Diabetes Care.* 2019;42:1939-1945. doi: 10.2337/dc19-0408
- 11 15. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ,
12 Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, et al.
13 Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med.*
14 2020;382:244-255. doi: 10.1056/NEJMoa1905239
- 15 16. Mohammedi K, Pigeyre M, Bosch J, Yusuf S, Gerstein HC. Arm and ankle blood pressure
16 indices, and peripheral artery disease, and mortality: a cohort study. *Eur Heart J.* 2024.
17 doi: 10.1093/eurheartj/ehae087
- 18 17. Ioannis Kosmidis ECKP, Nicola Sartori Mean and median bias reduction in generalized
19 linear models. *Statistics and Computing.* 2020;30:43-59. doi:
20 <https://doi.org/10.1007/s11222-019-09860-6>
- 21 18. European Society of Hypertension-European Society of Cardiology Guidelines C. 2003
22 European Society of Hypertension-European Society of Cardiology guidelines for the
23 management of arterial hypertension. *J Hypertens.* 2003;21:1011-1053. doi:
24 10.1097/00004872-200306000-00001
- 25 19. Yap T, Silickas J, Weerakkody R, Lea T, Santhirakumaran G, Bremner L, Diamantopoulos
26 A, Biasi L, Thomas S, Zayed H, et al. Predictors of outcome in diabetic patients
27 undergoing infrapopliteal endovascular revascularization for chronic limb-threatening
28 ischemia. *J Vasc Surg.* 2022;75:618-624. doi: 10.1016/j.jvs.2021.09.040
- 29 20. Giovanetti F, Gargiulo M, Laghi L, D'Addato S, Maioli F, Muccini N, Borghi C, Stella A.
30 Lipoprotein(a) and other serum lipid subfractions influencing primary patency after
31 infrainguinal percutaneous transluminal angioplasty. *J Endovasc Ther.* 2009;16:389-396.
32 doi: 10.1583/09-2733.1
- 33 21. Yanaka K, Akahori H, Imanaka T, Miki K, Yoshihara N, Kimura T, Tanaka T, Asakura M,
34 Ishihara M. Impact of lipoprotein(a) levels on primary patency after endovascular
35 therapy for femoropopliteal lesions. *Heart Vessels.* 2023;38:171-176. doi:
36 10.1007/s00380-022-02151-7
- 37 22. Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS,
38 Blomster JI, Fowkes FGR, Katona BG, et al. Association of Hypertension and Arterial
39 Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery
40 Disease: The EUCLID Trial. *Circ Cardiovasc Qual Outcomes.* 2020;13:e006512. doi:
41 10.1161/CIRCOUTCOMES.120.006512
- 42 23. Arinze N, Farber A, Levin SR, Cheng TW, Jones DW, Patel VI, Rybin D, Doros G, Siracuse
43 JJ. Perioperative outcomes after lower extremity bypass and peripheral vascular

- 1 interventions in patients with morbid obesity and superobesity. *J Vasc Surg.*
2 2020;71:567-574 e564. doi: 10.1016/j.jvs.2019.05.039
- 3 24. Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J, McBride PE.
4 Lower extremity peripheral arterial disease in hospitalized patients with coronary artery
5 disease. *Vasc Med.* 2003;8:233-236. doi: 10.1191/1358863x03vm506ra
- 6 25. Hishikari K, Hikita H, Nakamura S, Nakagama S, Mizusawa M, Yamamoto T, Doi J, Utsugi
7 Y, Sudo Y, Kimura S, et al. Usefulness of Lipoprotein(a) for Predicting Clinical Outcomes
8 After Endovascular Therapy for Aortoiliac Atherosclerotic Lesions. *J Endovasc Ther.*
9 2017;24:793-799. doi: 10.1177/1526602817728068
- 10 26. Guedon AF, De Freminville JB, Mirault T, Mohamedi N, Rance B, Fournier N, Paul JL,
11 Messas E, Goudot G. Association of Lipoprotein(a) Levels With Incidence of Major
12 Adverse Limb Events. *JAMA Netw Open.* 2022;5:e2245720. doi:
13 10.1001/jamanetworkopen.2022.45720
- 14 27. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA,
15 Genest J, Gregoire J, Grover SA, et al. 2021 Canadian Cardiovascular Society Guidelines
16 for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in
17 Adults. *Can J Cardiol.* 2021;37:1129-1150. doi: 10.1016/j.cjca.2021.03.016
- 18 28. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR,
19 Koschinsky M, Lambert G, Mach F, et al. Lipoprotein(a) in atherosclerotic cardiovascular
20 disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
21 *Eur Heart J.* 2022;43:3925-3946. doi: 10.1093/eurheartj/ehac361
- 22 29. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de
23 Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018
24 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
25 the Management of Blood Cholesterol: Executive Summary: A Report of the American
26 College of Cardiology/American Heart Association Task Force on Clinical Practice
27 Guidelines. *J Am Coll Cardiol.* 2019;73:3168-3209. doi: 10.1016/j.jacc.2018.11.002
- 28 30. Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S. Relationship between "LDL-C",
29 estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a)
30 lowering with an antisense oligonucleotide. *J Clin Lipidol.* 2018;12:702-710. doi:
31 10.1016/j.jacl.2018.02.014
- 32 31. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference
33 BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. *JAMA*
34 *Cardiol.* 2019;4:1287-1295. doi: 10.1001/jamacardio.2019.3780
- 35 32. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM,
36 Misra S, Ujueta F, American Heart Association Council on E, et al. Lower Extremity
37 Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future
38 Directions: A Scientific Statement From the American Heart Association. *Circulation.*
39 2021;144:e171-e191. doi: 10.1161/CIR.0000000000001005
- 40 33. Matveyenko A, Matienzo N, Ginsberg H, Nandakumar R, Seid H, Ramakrishnan R,
41 Holleran S, Thomas T, Reyes-Soffer G. Relationship of apolipoprotein(a) isoform size
42 with clearance and production of lipoprotein(a) in a diverse cohort. *J Lipid Res.*
43 2023;64:100336. doi: 10.1016/j.jlr.2023.100336

- 1 34. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V,
2 Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for
3 coronary heart disease. *Arterioscler Thromb Vasc Biol.* 1996;16:713-719. doi:
4 10.1161/01.atv.16.6.713
- 5 35. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in
6 cardiovascular disease? *J Lipid Res.* 2016;57:745-757. doi: 10.1194/jlr.R060582
- 7 36. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Jr.,
8 Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel
9 link between lipoproteins and thrombosis. *Blood.* 2001;98:2980-2987. doi:
10 10.1182/blood.v98.10.2980
- 11 37. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a)
12 (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease:
13 New Insights From a Large National Biobank. *Arterioscler Thromb Vasc Biol.*
14 2021;41:465-474. doi: 10.1161/ATVBAHA.120.315291
- 15 38. Sepehri Z, Masoumi M, Ebrahimi N, Kiani Z, Nasiri AA, Kohan F, Fathollahi MS, Arababadi
16 MK, Asadikaram G. Correction: Atorvastatin, Losartan and Captopril Lead to
17 Upregulation of TGF-beta, and Downregulation of IL-6 in Coronary Artery Disease and
18 Hypertension. *PLoS One.* 2017;12:e0172404. doi: 10.1371/journal.pone.0172404
- 19 39. Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL,
20 Rimm EB, Tsimikas S, et al. Oxidation-specific biomarkers and risk of peripheral artery
21 disease. *J Am Coll Cardiol.* 2013;61:2169-2179. doi: 10.1016/j.jacc.2013.02.047
- 22 40. Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, Bhatt DL, Storey
23 RF, Sabatine MS, O'Donoghue ML. Lipoprotein(a) and Benefit of Antiplatelet Therapy:
24 Insights From the PEGASUS-TIMI 54 Trial. *JACC: Advances.* 2023;2. doi:
25 10.1016/j.jacadv.2023.100675
- 26 41. Cui K, Yin D, Zhu C, Song W, Wang H, Jia L, Zhang R, Wang H, Cai Z, Feng L, et al. How Do
27 Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable
28 Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After
29 Percutaneous Coronary Intervention? *J Am Heart Assoc.* 2022;11:e023578. doi:
30 10.1161/JAHA.121.023578
- 31 42. Marlys L. Koschinsky AB, Michael B. Boffa, Dave L. Dixon, Keith C. Ferdinand, Samuel S.
32 Gidding, et al. A Focused Update to the 2019 NLA Scientific Statement on Use of
33 Lipoprotein(a) in Clinical Practice. *Journal of Clinical Lipidology.* 2024.
34

Table I. Baseline characteristics, lipid, and lipoprotein levels

Characteristic	Study Sample		
Age, y	66.7 ± 9.7		
Range for age	43-79		
BMI, kg/m ²	28.1 ± 5.3		
<i>Race</i>	<i>Female (N=12)</i>	<i>Male (N=13)</i>	
White	5	7	
Black	3	5	
Hispanic	4	1	
<i>Clinical Characteristics, n(%)</i>			
Diabetes mellitus	14 (56%)		
Hypertension	21 (84%)		
Hyperlipidemia	20 (80%)		
History CAD	7 (28%)		
Prior coronary event	4 (16%)		
Ever smoker	20 (80%)		
<i>Medical therapy, n(%)</i>			
Statin	19 (76%)		
Beta-blocker	12 (48%)		
DAPT or AP + DOAC	22 (88%)		
DOAC alone	1 (4%)		
AP alone	2 (8%)		
Total cholesterol, mg/dL	159 ± 46.1		
Triglycerides, mg/dL	148 (105, 238)		
HDL-C, mg/dL	39.8 ± 14.0		
Calculated-LDL, mg/dL*	78.7 ± 34.8		
Apo(a) weighted isoform size	18.4 ± 4.1		
	<i>Black</i>	<i>Hispanic</i>	<i>White</i>
Plasma Lp(a), nmol/L	68.3 (34.0, 304.1)	228.6 (67.0, 333.0)	125.9 (80.1, 191.3)
Plasma apoB100, mg/dL	167.7 ± 45.1	225.6 ± 83.7	144.3 ± 59.2

Legend: ± represents Mean and Standard Deviation; () represents Median and Interquartile Range.

*Calculated LDL-C means reported for N=24, one subject had >400 mg/dL TG levels (Supplemental Table I).

Coronary artery disease (CAD); direct oral anticoagulant (DOAC), antiplatelet (AP), dual antiplatelet therapy (DAPT)

Table IIa. Effects of apo(a) *wIS* on surgical outcomes

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
Δ Symptoms	25	0.25 (-1.01, 1.50)	p=0.70
Primary patency	23	-2.81 (-5.57, -0.04)	p <0.05*
Δ ABI	14	0.30 (-2.43, 3.01)	p=0.84
Re-Intervention	25	-0.53 (-2.59, 1.54)	p=0.07

Table IIb. Effects of Lp(a) on surgical outcomes

Outcome	Sample (N)	Firth Model Estimate (95% CI)	p Value
Δ Symptoms	25	0.17 (-0.89, 1.23)	p=0.75
Primary patency	23	0.32 (-0.68, 1.33)	p=0.53
Δ ABI	14	0.92 (-1.57, 3.41)	p=0.47
Re-intervention	25	0.13 (-0.89, 1.15)	p=0.80

Legend: PAD: Peripheral Arterial Disease; *wIS*: weighted Isoform Size; Δ ABI: change in Ankle Brachial Index; Δ Symptoms: change in symptoms, *wIS* and Lp(a) were standardized, *statistical significance = $p < 0.05$; Firth model: exponential estimate (95% CI). Available number of subject data for each outcome (N=X) are provided. Complete ABI data is missing in 11 subjects

Table III. Comparison of inflammatory marker levels in Study Subjects and Healthy Controls.


Marker	PAD Cohort	*Healthy Controls
IL-6 (pg/mL)	3.3±2.5	0.01-11.5 ³⁸
IL-18 (pg/mL)	274.2±147.5	80–120 ³⁹
hs-CRP (mg/dL)	3.6±4.6	<0.3 ⁴⁰
TNF α (pg/mL)	1.4±0.7	0 - 2.2

Legend: \pm represents Mean and Standard Deviation; IL: Interleukin; CRP: C-reactive protein; TNF: Tumor Necrosis

Factor. Study Cohort N=25. *Healthy controls from published literature

1 **Figure 1.** Negative relationship between Lp(a) levels and *wIS*

2



3


4 Legend: Lp(a): Lipoprotein(a); *wIS*: weighted Isoform Size.

5

6

7

1 **Figure 2.** Apo(a) size distribution by Lp(a) level quartiles (nmol/L)



2
3 Legend: Lp(a): Lipoprotein(a). Gray: small apo(a) isoforms; Black: large apo(a) isoforms. All data presented as
4 percentages of study subjects and absolute numbers in ().

5

1 **Supplemental Data**

2
3 **Supplemental Table I. Individual Subject Data**


4

Subject Number	Lp(a) (nmol/L)	Isoform 1	% Isoform 1	Isoform 2	% Isoform 2	wIS	SRRE
1	300.99	14	8%	25	18%	15.98	B
2	97.10	17	97%	21	3%	17.12	W
3	92.56	20	78%	31	22%	22.42	W
4	3.40	19	82%	30	18%	20.98	B
5	4.12	27	100%			27	B
6	73.82	14	78%	26	22%	16.64	B
7	193.26	18	100%			18	W
8	190.63	13	100%			13	W
9	228.60	18	82%	24	18%	19.08	H
10	43.91	28	96%	34	4%	28.24	B
11	397.62	17	100%			17	H
12*	305.28	16	100%			16	W
13	108.34	13	91%	18	9%	13.45	W
14	448.08	17	100%			17	W
15	332.96	14	90%	13	10%	13.9	H
16	42.62	13	99%	29	1%	13.16	W
17	313.38	17	100%			17	B
18	<2.80	15	100%			15	W
19	63.84	24	100%			24	B
20	42.47	19	84%	24	16%	19	H
21	156.73	19	100%			19	W
22	67.04	23	100%			23	H
23	7.05	15	81%	32	19%	18.23	W
24	143.43	21	100%			21	W
25	556.02	14	99%	29	1%	14.15	B

5 Legend: wIS – weighted Isoform Size; SRRE – Self Reported Race/Ethnicity. B-Black, W-White, H-Hispanic. Large isoform ≥ 22 ,
6 Small isoform < 22 . *Calculated LDL-C not reported (TG levels > 400 mg/dL).

8 **Supplemental Figure 1.** Apo(a) weighted isoform sizes in re-operative patients

9




10

11 Legend: wIS – weighted Isoform Size, Subject Number (N) underwent re-operation at 3-6 months.

12

13 **Supplemental Figure 2.** ABALEAR study CONSORT flow diagram



14
15 Legend: LE—lower extremity; US—ultrasound; ABI—ankle brachial index; N—sample number